The Peptide Wiki
Mapping Knowledge.
Advancing Discovery.
📩 Subscribe
// STATE LEGISLATION TRACKER

Kentucky HB 750 — AN ACT relating to cychlorphine.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown
State
Kentucky
Bill
HB 750
Filed
2026-02-25
Read the bill
OpenStates →
Last reviewed
2026-06-21

Plain-English Summary

Kentucky HB750 appears to target cychlorphine by adding it to Kentucky controlled-substance and trafficking laws. Based on the available title, subjects, and bill text, it does not directly regulate compounded peptides, peptide prescribing, 503A/503B pharmacies, naturopathic scope, NP scope, or peptide telehealth access.

Key Points

  • No direct change to compounded peptide access is shown.
  • The bill focuses on cychlorphine, not peptide therapies.
  • Telehealth is mentioned in existing definitions, not newly expanded or restricted.
  • No specific FDA 503A or 503B compounding rule appears in the available text.
  • Peptide clinics should only care if they handle controlled substances.

What to Watch For

i
Note Track whether later amendments add broader controlled-substance, prescribing, or telehealth language.
i
Note Cychlorphine enforcement may affect drug-control compliance, but not ordinary peptide prescribing.
!
Concern If amended to cover analogues broadly, clinics using research compounds should review the final language.

Where the Bill Stands

OpenStates did not provide a latest action, so the current procedural status cannot be confirmed from the supplied source.
— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.
Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws